Effect of Probiotic Supplementation on Renal Function, Vascular Calcification and Alterations in Bone Mineral Metabolism in Patients With Chronic Kidney Disease
NCT07260682 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84
Last updated 2025-12-03
Summary
INTRODUCTION You have been asked to participate in a research study of patients with chronic kidney disease to assess whether a probiotic supplement (a commercially available product that is not a medication) can help slow the progression of your vascular calcification and thus improve your health. Your participation in this study does not replace your usual medical care.
Why is this study being conducted? The purpose of this study is to demonstrate that a probiotic supplement is helpful in slowing the progression of your vascular calcification. We also intend to assess whether changes in vascular calcification are associated with changes in mineral metabolism parameters, inflammation, and kidney function.
What does the study involve? This study will include patients with chronic kidney disease and vascular calcification.
Half of the patients will receive the probiotic supplement Probimel at a dose of 15 ml per day. The study will last 6 months, during which time your kidney function, vascular calcification, and parameters related to uremic toxins, inflammation, and mineral metabolism will be evaluated. The study physician may adjust the dosage of your usual medication before you begin using the study food product, or during the study if your symptoms change. Please ask your study physician or team any questions you may have.
STUDY PROCEDURES If you agree to participate in this study and sign this Consent Form, you will undergo some tests during a screening period to determine if you are eligible to participate. This screening takes place before your inclusion in the main phase of the study.
At each study visit, you will be asked about:
* any medications you are currently taking or any changes to them,
* any problems you are experiencing,
* any side effects you may be having, which may or may not be related to the study,
* whether you have visited any other doctors or hospitals.
Following the explanation of the research project and the signing of informed consent during the initial screening visit, the patient's medical history will be reviewed, anthropometric measurements will be taken, and existing biochemical data will be analyzed.
During the first visit, blood will be drawn, stool samples will be collected, and the degree of vascular calcification will be assessed using abdominal, pelvic, and hand X-rays. The study and treatment with the probiotic supplement will begin at this point.
Subsequent visits will be scheduled at 2 and 6 months, during which blood samples (hematology and biochemistry) will be taken. Additionally, at the final visit (month 6), stool collection and X-rays will be repeated.
At this point, treatment will be discontinued, and the study will be concluded, with a final follow-up visit scheduled to ensure that all studied parameters are stable and within the normal range. Excess blood samples from this study will be stored in the Biobank of the Reina Sofía University Hospital in Córdoba and may be used later in other scientific studies. For this reason, you will receive an additional document in which you give your consent for the proper storage of the samples in the biobank.
What should I do during the study?
To obtain reliable information from this study on the effect of probiotic supplementation in patients with chronic kidney disease and vascular calcification, you are expected to do the following:
* Follow your study physician's instructions.
* Attend all scheduled study visits and complete all procedures.
* Review all medications you are taking with your study physician. Certain medications you are currently taking or have taken in the past may prevent you from participating in this study.
* Some procedures/illnesses you have had in the past may prevent you from participating in this study. • Take and store your study medication as directed, and return any leftover medication and/or empty containers to your doctor at each visit.
* Do not share your study medication with anyone. You are the only person authorized to take it.
* Keep your study medication and materials out of the reach and sight of children and anyone who cannot read or understand all the information about it.
* Tell the study staff about any health problems you have, even if you think they are not important.
* Tell the study staff if you wish to stop participating in this study.
* Do not participate in any other research studies.
Conditions
- Chronic Kidney Disease (Stages 3b-5)
Interventions
- DIETARY_SUPPLEMENT
-
Probiotic
Supplement: Lactobacillus DMG0017 Probimel Dosage: 15 ml/day for 6 months. Directions: Take alone or diluted in juice, any sugary drink, or yogurt. Pharmaceutical Form: Lactobacillus oral solution Route of administration: oral
Sponsors & Collaborators
-
Maimónides Biomedical Research Institute of Córdoba
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-12
- Primary Completion
- 2023-01-10
- Completion
- 2023-01-10
Countries
- Spain
Study Locations
More Related Trials
-
Effects of Probiotics on the Patients With End Stage Renal Disease (ESRD)
NCT03010735 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Use of Oral Probiotics to Reduce Urinary Oxalate Excretion
NCT00587041 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation Of The Efficacy of a Strain-Specific Probiotic Formulation in Hemodialysis Patients
NCT03066921 ·Status: COMPLETED ·Phase: NA
-
Probiotics and Low Protein Diet in Advanced Chronic Kidney Disease
NCT04204005 ·Status: COMPLETED ·Phase: NA
-
Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD
NCT02302287 ·Status: UNKNOWN ·Phase: PHASE4
-
Study the Effect of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Level in Hemodialysis Patients
NCT06421883 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
The Effect of Probiotics on Depression Syndrome and Risk Factors of Cardiovascular Disease in Hemodialysis Patients
NCT05724511 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients
NCT02999204 ·Status: COMPLETED ·Phase: PHASE4
-
Pentoxifylline for Vascular Calcification in Kidney Disease
NCT06903689 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
The Effects of Synbiotic on Cardiovascular and Bone Metabolism Markers in Transplanted Kidney Patients
NCT06160830 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effects of Synbiotics Supplementation on the Uremic Toxin Indoxyl Sulfate Level and Constipation in End-stage Renal Disease Patients Undergoing Hemodialysis
NCT04527640 ·Status: UNKNOWN ·Phase: NA
-
Modulation of Gut Microbiota in End-stage Renal Disease
NCT02568891 ·Status: WITHDRAWN ·Phase: NA
-
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
NCT00379899 ·Status: COMPLETED ·Phase: PHASE4
-
lncRNAs as a Biomarker to Assess the Therapeutic Impact of Oral Absorbent ± Probiotics in CKD Patients With PAD
NCT04788914 ·Status: RECRUITING ·Phase: NA
-
Effectiveness of Probiotics to Treat End Stage Renal Disease
NCT02929225 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2
NCT01561222 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Changes in Dialysate Bicarbonate on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients
NCT06084858 ·Status: COMPLETED ·Phase: NA
-
Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease
NCT04819217 ·Status: RECRUITING ·Phase: NA
-
Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients
NCT01173848 ·Status: TERMINATED ·Phase: PHASE3
-
Impact of Low Protein Diet Supplemented With Ketoanalogues Supplementation on Uremic Toxins Production
NCT03959228 ·Status: UNKNOWN ·Phase: PHASE3
-
Observational Study of Kibow Biotics in Dialysis Patients
NCT01450670 ·Status: COMPLETED
-
Study of Oral Uremic Toxin Absorbent/Probiotics to Modulate Systemic Inflammation and Retard the Progression of Chronic Kidney Disease in Patients With Diabetes.
NCT07333313 ·Status: RECRUITING ·Phase: NA
-
Queen's University Investigation of Calcification in Chronic Kidney Disease
NCT00687661 ·Status: COMPLETED ·Phase: PHASE3
-
Vitamin D and Coronary Calcification Study
NCT00752102 ·Status: COMPLETED ·Phase: PHASE4
-
Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients
NCT02718885 ·Status: COMPLETED ·Phase: EARLY_PHASE1